Workshop on Monoclonal Antibodies in Cancer

October 1, 2010
Hyatt Regency Washington on Capitol Hill
Washington, D.C.

The primary audience for the 2010 Workshop included scientists and clinicians from regulatory agencies, industry, and academics who are interested in understanding more about monoclonal antibodies (mAbs). The Workshop facilitated interactive discussion on mechanisms of action responsible for clinical efficacy of monoclonal antibodies, mechanisms of resistance to monoclonal antibodies and how to best utilize current knowledge to develop more effective antibody-based cancer treatments.

Topics Included:

  • Antibody Engineering
  • Investigating Antibodies as "Vaccines"
  • Immunomodulatory Antibodies
  • Lessons Learned from Antibody Therapy in Other Disease
  • Tumor-Targeting Antibodies


Glenn Dranoff, MD
Dana-Farber Cancer Institute

Ira Mellman, PhD
Genentech, Inc.

George J. Weiner, MD
University of Iowa



View the 2010 iSBTc program supporters.


The Workshop on Monoclonal Antibodies in Cancer is a non-accredited continuing medical education event. No credits are offered for physician participation in this educational program.